BMY - Bristol-Myers Squibb Company
48.42 +0.20 (0.41%)
Pre-market: 8:05AM EDT
| Previous close | 47.56 |
| Open | 47.79 |
| Bid | 48.27 x 1200 |
| Ask | 48.46 x 1300 |
| Day's range | 47.65 - 48.47 |
| 52-week range | 44.30 - 63.69 |
| Volume | 8,524,875 |
| Avg. volume | 15,067,004 |
| Market cap | 78.858B |
| Beta (3Y monthly) | 0.79 |
| PE ratio (TTM) | 15.35 |
| EPS (TTM) | 3.14 |
| Earnings date | 25 Jul 2019 |
| Forward dividend & yield | 1.64 (3.61%) |
| Ex-dividend date | 2019-07-03 |
| 1y target est | 56.10 |
- Motley Fool•2 days ago
Is It Too Late to Buy Celgene Stock?
The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?
- Zacks•4 days ago
3 Big Pharma Stocks to Buy Right Now
These big pharma stocks all have a Zacks Rank 2 or better.
- Zacks•4 days ago
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
- Business Wire•4 days ago
Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM
- Zacks•5 days ago
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
- Business Wire•5 days ago
Bristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
- Business Wire•5 days ago
New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
Bristol-Myers Squibb Company (BMY) today announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA® (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients seropositive for certain autoantibodies. Among 80 adult patients with early (≤ 12 months from symptom onset) moderate-to-severe RA who had never been treated with a biologic medication and tested positive for autoantibodies called anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF), numerically higher efficacy responses were seen with ORENCIA at week 24. ACR 20/50/70 scores for adalimumab were 63, 45 and 30, respectively.
- Zacks•6 days ago
Roche's Rituxan Gets Priority Review for Blood Disorder
Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
- Zacks•6 days ago
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
- Zacks•6 days ago
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.63, marking a +1.62% move from the previous day.
- Zacks•6 days ago
Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
- Zacks•6 days ago
Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
- Zacks•6 days ago
Boost Your Portfolio's Health With These 3 Big Drug Stocks
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
- Zacks•7 days ago
Insys Down on Bankruptcy News Amid Increasing Legal Expenses
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
- Zacks•7 days ago
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
- Zacks•7 days ago
Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
- Zacks•8 days ago
Sanofi (SNY) in Focus: Stock Moves 5.5% Higher
Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
- Zacks•11 days ago
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
- Zacks•11 days ago
Novartis Appoints New Pharma Unit Head, Gives Other Updates
Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
- Zacks•12 days ago
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Bristol-Myers Squibb (BMY) closed at $46.15 in the latest trading session, marking a -1.03% move from the prior day.
- Zacks•12 days ago
Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.
- Zacks•12 days ago
Mallinckrodt Down After Agreement with DOJ for Litigation
Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.
- Motley Fool•12 days ago
Top 5 Stocks in the Fight Against Cancer
These stocks are leading the way in their respective areas in battling cancer.
- Zacks•12 days ago
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
